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Mobilization of hematopoietic stem cells (HSCs) from bone marrow (BM) to peripheral blood
(PB) by cytokine granulocyte colony-stimulating factor (G-CSF) or the chemical antagonist of
CXCR4, AMD3100, is important in the treatment of blood diseases. Due to clinical conditions of
each application, there is a need for continued improvement of HSC mobilization regimens.
Previous studies have shown that genetic ablation of the Rho GTPase Cdc42 in HSCs results in
their mobilization without affecting survival. Here we rationally identified a Cdc42 activityspecific inhibitor (CASIN) that can bind to Cdc42 with submicromolar affinity and competitively
interfere with guanine nucleotide exchange activity. CASIN inhibits intracellular Cdc42 activity
specifically and transiently to induce murine hematopoietic stem/progenitor cell egress from the
BM by suppressing actin polymerization, adhesion, and directional migration of stem/progenitor
cells, conferring Cdc42 knockout phenotypes. We further show that, although, CASIN
administration to mice mobilizes similar number of phenotypic HSCs as AMD3100, it produces
HSCs with better long-term reconstitution potential than that by AMD3100. Our work validates a
specific small molecule inhibitor for Cdc42, and demonstrates that signaling molecules

Yi Zheng yi.zheng@cchmc.org.
Author contributions W.L. and W.D. designed and performed the research, analyzed the data, and wrote the paper. X.S., L.W., C.E.,
M.C.F., M.A.R., A.R., X.Z., K.S., F.G., performed some of the experiments. N.N., J.M., H.G., and Q.P. designed the research. Y.Z.
designed the research, analyzed the data, and wrote the paper.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Electronic supplementary material The online version of this article (https://doi.org/10.1038/s41375–018-0251–5) contains
supplementary material, which is available to authorized users.

Liu et al.

Page 2

Author Manuscript

downstream of cytokines and chemokines, such as Cdc42, constitute a useful target for long-term
stem cell mobilization.

Introduction

Author Manuscript

Hematopoietic stem cells (HSCs) are a rare population of cells residing in a unique bone
marrow (BM) micro-environment (also known as niche), that undergo a complex but highly
ordered hematopoiesis program throughout the life-span of mammals [1–5]. In addition to
supporting blood cell development, HSCs are characterized by their self-renewal ability, a
property that explains the mostly conserved HSC numbers found in animals [1, 4, 6]. HSC
transplantation has become a standard care for the treatment of many hematologic
malignancies, including chemotherapy sensitive relapsed acute leukemia or lymphoma, and
for some non-malignant diseases, such as BM failure in Fanconi anemia [7–11]. Under
physiological conditions, few HSCs circulate in peripheral blood (PB) [12]. The induced
movement of HSCs from BM into PB is termed HSC mobilization. Mobilized PB stem cells
have become a preferred stem cell source for autologous transplantation, and are widely
used for allogeneic stem cell transplantation [13–16].

Author Manuscript

G-CSF is the standard of care in mobilizing HSCs for transplantation. However, broad interindividual variability exists in response to this mobilization regimen, and poor HSC
mobilization in response to G-CSF is often found in patients who have been treated for
cancer or who have genetic disorders [8, 9, 17]. AMD3100, a CXCR4 antagonist, has been
used alone or in combination with G-SCF to mobilize stem cells [18–21]. A recent study
found that AMD3100 mobilizes a different set of HSCs than G-CSF [19], raising the
possibility that the PB stem cells collected by these two regimens may have different
properties. Indeed, a more recent study using AMD3100 in combination with CXCR2
agonist, GROβ shows a preferential trafficking of stem cells with high-engraftment
efficiency resulted from synergistic signaling on neutrophils [22]. Hence, development of
new methods to mobilize HSCs, alone or in combination with existing regimens, will
continue to have therapeutic value to further improve transplant outcomes.

Author Manuscript

The Rho family small GTPase Cdc42 regulates actin organization, cell–cell and cellextracellular matrix adhesions, and directional movement in many cell types [23, 24]. In
HSCs, Cdc42 integrates signals from multiple cell surface receptors—including c-Kit,
CXCR4, and β1 integrin—to regulate cytoskeleton dynamics that affects cell polarity,
adhesion and migration properties in normal HSC maintenance [25–27]. Unlike the related
Rac1 and Rac2 GTPases [28, 29], Cdc42 is not required for HSC survival or proliferation
but is essential in mediating HSC homing, lodging, and retention in the bone marrow niche
[25]. Studies of a Cdc42 gain-of-activity using the Cdc42GAP knockout mouse model have
revealed that constitutively elevated Cdc42 activity similarly causes defective adhesion and
migration leading to decreased engraftment of HSCs [30], suggesting that a precise
regulation of Cdc42 activity is required for retaining HSCs in the BM niche. The current
studies are aimed to develop a new concept, i.e., pharmacologic targeting of Cdc42 is of
therapeutic value for effective mobilization of LT-HSCs thus benefiting stem cell harvest, in
preclinical mouse models. Our work not only stringently examines the effect of Cdc42
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targeting in HSC mobilization, but also validates a lead small molecule inhibitor specific for
Cdc42 activity that could be broadly useful to study biological and pathological roles of
Cdc42 in blood and other tissue cells.

Materials and methods
Animals
C57Bl/6 and congenic BoyJ mice were obtained from The Jackson Laboratory (Bar Harbor,
ME). Animals were maintained in the animal barrier facility at the Cincinnati Children’s
Hospital Medical Center. All animal procedures were approved by the Institutional Animal
Care and Use Committee of Cincinnati Children’s Hospital Medical Center prior to study
initiation (IACUC protocol # 2013–0159).

Author Manuscript

CASIN
CASIN and its inactive analog (referred to Peterson et al., as Pirll-related compound 2 and 7,
respectively) [31] were obtained from Chembridge Corporation, and purified to >99% by
high-performance liquid chromatography. For in vitro studies, CASIN (containing 0.02–
0.2% DMSO) was used at 2–20 μM in IMDM. For in vivo experiments, CASIN was
dissolved in PBS with 15% ethanol, and administered by IP (2.4 mg/kg) or IV (1.2 mg/kg)
injection. Separately, C57Bl/6 mice were treated with AMD3100 at 5 mg/kg by IP.
Flow cytometry
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HSPCs were immunophenotyped using FACS analysis with the phenotypic antibodies
IL-7Rα-APC-cy7, c-Kit-APC, Sca-1-PE, CD34–FITC, FcRII/III (CD16/32)-PE-cy7, as well
as biotinylated lineage-depletion cocktail labeled with the secondary antibody Percp-cy5streptividin. The sub-compartments of HSPCs, including LT-HSC and ST-HSC were then
quantified accordingly. Moreover, LT-HSCs are also defined by FCAS analysis using
antibodies of LSK as above together with CD150-PE-cy7, CD48/41-FITC. Blood cell
differentiation was determined by the flow cytometry after staining with CD3, B220,
CD11b, Gr1, and Ter119. Cell cycle and apoptosis were determined by flow cytometry after
BrdU labeling and and/or annexinV and 7AAD staining.
CFU determination of HPC mobilization
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C57Bl/6 mice were mobilized with CASIN (1.2 mg/kg, IV), and progenitor cell numbers in
PB were determined at 0.5, 1, 2, and 4 h post CASIN injection. At each time point, 200 μl of
PB was added to 4 ml of cytokine-containing methylcellulose (Stem Cell Technologies,
Vancouver, Canada) and plated in triplicate in 35 mm-gridded dishes. Colonies were
enumerated 7 days post plating. Separately, C57Bl/6 mice were treated with AMD3100 at 5
mg/kg by IP or with huG-CSF (Amgen) at 12.5 μg/kg in PBS/0.1% BSA by IP at 100 μg/kg
per day once a day for 5 days and animals were analyzed on day 6. In the combinatory
treatment, CASIN was administrated by IV (1.2 mg/kg) injection on day 6 of G-CSF
regimen or together with AMD3100 and PB samples were analyzed 2 h post CASIN
treatment.
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Groups of donor CD45.2 C57B1/6 mice (n = 4) were treated by IV injection of CASIN and
vehicle control and IP injection of AMD3100. Mobilized PB were collected 2 h after by
cardiac puncture. Recipient CD45.1 BoyJ mice (n = 4) were lethally irradiated (11.75 Gy)
prior to transplantation and injected intravenously with PBMC from 500 μl PB. Morbidity
was examined everyday by 2 weeks and weekly until month 4 when the secondary
transplantation was performed using 5 × 106 BM cells of the primary recipients. Chimerism
was analyzed by the flow cytometry on total, CD3+, B220+, Gr1+, Ter119+, and LSKCD34–
population of PB and BM cells.
For detailed experimental procedures, see Supplemental Methods.

Results
Author Manuscript

Cdc42 activity-specific inhibitor, CASIN, specifically inhibits Cdc42 guanine nucleotide
exchange activity

Author Manuscript

In search of a Cdc42-specific small molecule inhibitor, we examined compounds, including
Pirl that show inhibitory activity in an in vitro Xenopus oocyte lysate assay of actin
polymerization induced by Phosphatidylinositol 4,5-bisphosphate (PIP2) [31], which may
directly involve the Cdc42-WASP (Wiskott-Aldrich syndrome protein) signaling cascade.
An analog of Pirl, the lead chemical for F-actin inhibition reported by Peterson [31], which
we term Cdc42 activity-specific inhibitor (CASIN; Fig. 1a), was found to confer the most
active Cdc42 binding activity in an in vitro binding assay, in which purified proteins were
labeled with fluorescence dye and microscale thermophoresis were measured by a
NanoTemper Monilith Instrument [32], in comparison with Pirl1 and another inactive analog
(Fig. 1b, S1). CASIN directly interacted with purified Cdc42 with an affinity of 332 ± 101
nM Kd (Fig. 1b) and did not bind to related Rho GTPase RhoA, Rac1, RhoJ, RhoU, or
RhoV, nor the Cdc42 guanine nucleotide exchange factor (GEF) intersectin (Fig. 1b and
S2A, S2B). In the GEF reaction of Cdc42 catalyzed by the DH-PH module of intersectin
GEF, CASIN showed a dose-dependent inhibition of GEF-induced dissociation of GDP
from Cdc42; whereas in similar experiments CASIN did not affect RhoA guanine nucleotide
exchange reaction catalyzed by the RhoA-specific GEF, LARG (Fig. 1c). These data
indicate that CASIN binds specifically to Cdc42-GDP. When CASIN were examined in
fibroblast cells, we found that it inhibited bradykinin-induced F-actin morphologic changes
of wild-type (WT) mouse embryonic fibroblast (MEF) cells but showed no effect on
Cdc42−/− cells that are resistant to bradykinin stimulation (Figure S3). Thus, CASIN can
directly bind to Cdc42 and specifically inhibit Cdc42 GEF reaction.

Author Manuscript

CASIN inhibits Cdc42 activity, F-actin polymerization, and polarization of blood
progenitors
To examine the effect of CASIN in inhibiting Cdc42 activity in primary hematopoietic cells,
murine low-density bone marrow (LDBM) cells were treated with CASIN, and the effect on
endogenous Cdc42-GTP species was determined by an effector-domain pull-down assay
[27, 29]. As shown in Fig. 2a, 5 μM CASIN could suppress Cdc42-GTP formation, but not
Rac1 activity, activated by stem cell factor (SCF), Stromal cell-derived factor 1α (SDF-1α)
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or fibronectin. Further, CASIN caused a dose-dependent inhibition of SDF-1α-induced
Cdc42 activation without affecting the activity of the closely related Rac1 or RhoA, and
removal of CASIN by a wash of the cells restored Cdc42 responsiveness to SDF-1α (Fig.
2b; data not shown). CASIN also induced a dose-dependent suppression of polarized
distribution of Cdc42 and tubulin in blood progenitor cells (Fig. 2c). Similar effects of
CASIN were observed in F-actin polymerization and polarity assays of primitive long-term
HSCs (LT-HSCs; Fig. 2d, S4). CASIN, on the other hand, did not alter the maturation of
primary hematopoietic progenitor cells (HPCs) into multi-lineage progenitors detected by
colony-forming assays (Fig. 2e). These results suggest that CASIN can selectively and
reversibly inhibit Cdc42 activity regulated by cytokine, chemokine, and adhesion molecules
in HPCs without affecting HPC differentiation.

Author Manuscript

CASIN dose-dependently suppresses adhesion and migration of wild-type blood
progenitor cells but has no effect on Cdc42−/− HPCs

Author Manuscript

To further ascertain the functional specificity of CASIN, we next examined the effect of
CASIN on the Cdc42-regulated cellular functions in WT and Cdc42−/− HPCs. In WT but not
Cdc42−/− Lin– BM cells (enriched for HPCs), CASIN was effective in suppressing basal and
SDF-1α stimulated Cdc42 activity but did not affect Rac1-GTP formation (Fig. 3a),
consistent with our observation that CASIN directly and specifically interacts with purified
Cdc42 but not other Rho GTPases, including Rac1 and RhoA (Fig. 1b, S2). CASIN
treatment of Lin– BM cells led to a dose-dependent inhibition of adhesion to fibronectin by
colony-forming cells, and impairment of directional migration toward a SDF-1α gradient by
colony-forming unit (CFU) cells, mimicking that of Cdc42 gene deletion when it was used
at a higher dosage (Fig. 3b, c). While CASIN dose-dependently suppressed adhesion and
directional migration activities of WT Lin– BM cells to the extent of Cdc42−/− cells, no
additive cellular effects of CASIN in these assays were detected upon CASIN treatment of
Cdc42−/− Lin– BM cells (Fig. 3b, c). More importantly, CASIN treatment did not affect
proliferation of WT or Cdc42−/− LDBM cells (Fig. 3d), allowing Cdc42−/− cells to retain a
higher proliferative activity than WT cells as previously observed [25]. In primary HPCs,
CASIN inhibited several known Cdc42 downstream-signaling events, including phosphorPAK1, phosphor-WASP, and phosphor-aPKC, similar to that by Cdc42 gene deletion (Fig.
3e). Together, these results indicate that CASIN suppresses adhesion and migration but does
not affect the proliferation of HPCs. Importantly, CASIN does not appear to have detectable
effects on Cdc42−/− bone marrow cells.
CASIN specifically inhibits Cdc42 activity and Cdc42-mediated signaling in HSPCs

Author Manuscript

To probe for the molecular mechanism of CASIN action, we transduced hematopoietic stem
and progenitor cells (HSPCs) from Cdc42−/− mice with lentiviral vector expressing a
constitutive active Cdc42 mutant, Q61L (Cdc42-Q61L), and found that CASIN was
incapable of suppressing F-actin polymerization in Cdc42−/− HSPCs expressing the Cdc42Q61L mutant protein (Fig. 4a), suggesting that CASIN acts at the activation site but not the
effector site of Cdc42. We also carried out a simulation of CASIN binding to the Cdc42
three-dimensional (3D) structure and found that CASIN can interact with a surface groove
of Cdc42 that is required for interaction with GEFs such as DOCK180 (Fig. 4b). Further,
mutational analysis of surface residues of Cdc42 reveals that Cdc42-M45E mutation at the
Leukemia. Author manuscript; available in PMC 2020 March 01.
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GEF action site resulted in a loss of the binding activity to CASIN in vitro (Fig. 4c) and the
unresponsiveness to CASIN in cells where endogenous WT Cdc42 was readily inhibited by
CASIN (Fig. 4d). Collectively, these results indicate that CASIN selectively inhibits Cdc42
activity and Cdc42-mediated signaling in HSPCs.
CASIN induces mobilization of HSCs in mice

Author Manuscript

Adult HSCs reside primarily in the BM, with only a small faction in the peripheral blood
(PB) under normal physiologic conditions [3, 12, 33]. Previous gene targeting experiments
in mice have found that Cdc42 knockout in mice results in massive mobilization of HSCs
from the BM to the peripheral [25]. To examine whether CASIN could mobilize HSCs in
mice, we applied a protocol of intravenous (IV) injection of CASIN to C57Bl/6 mice.
Pharmacokinetic analysis indicates that CASIN concentration in the serum of injected
animals was quickly reduced from 20 μM to less than the effective concentration of 0.5 μM in
~30 min (Fig. 5a, S5), suggesting that the effect of CASIN is transient. IV injection of
CASIN in mice resulted in a marked inhibition of Cdc42 activity in LDBM hematopoietic
cells in vivo (Fig. 5b). Colony-forming unit in culture (CFU-C) assay showed that CASIN
was able to induce a fourfold increase of progenitor activities in the peripheral blood (PB)
compared to controls 2 h after CASIN injection (Fig. 5c). Concomitant with the CASINinduced increase in colony-forming activity in PB, a significant increase in progenitor
activity was observed in spleen and liver of the mice (Fig. 5d). Consistent with the lack of
effect on Cdc42−/− cells in vitro, the effect of CASIN in mobilizing HPCs appears to be
specific through Cdc42, as CASIN administration showed no additive effect on mobilized
CFU-C activity in Cdc42−/− mice (Fig. 5e).

Author Manuscript

To examine potential toxicity of transient CASIN treatment, both long-term IV and IP
injection protocols of CASIN into mice in a broad range of dosages (0.1–5 mg/kg) were
tested. No detectable toxicity on multi-lineage blood differentiation were observed by either
H&E staining or marker FACS analysis of the BM, liver, spleen, and PB up to a period of 6
months of daily injection (Figure S6 and data not shown). Further, CASIN does not appear
to alter the survival or cell cycle status (Figure S7 and data not shown) and mobilizes BM
HSPCs that confer all different lineages of cells (Fig. 5f) in the treated mice. Taken together,
these results demonstrate that CASIN is safe and effective in mobilizing blood progenitors in
vivo.
CASIN-mobilized HSCs are superior in functionality to those mobilized by AMD3100

Author Manuscript

Cytokine granulocyte colony-stimulating factor, G-CSF and a CXCR4 antagonist,
AMD3100 have become the standard of care in mobilizing HSCs for transplantation.
AMD3100 has been clinically used alone or in combination with G-SCF to mobilize stem
cells [18–21]. To determine the potential applicability of CASIN in preclinical settings, we
then attempted to compare the mobilization capacity of CASIN, over AMD3100 or G-CSF.
In a progenitor colony-forming unit (CFU) activity assay, we found that all 3 agents were
able to mobilize progenitor cells from BM to peripheral blood, with G-CSF treated mice
showing the greatest CFU activity in PB (Fig. 6a). Since G-CSF has non-responders and
potential issue on growth stimulation in the clinics, and since G-CSF administration requires
a distinct 5-day injection protocol, we decided to focus on a comparison of CASIN with
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AMD3100, a small molecule antagonist of CXCR4 which shares signaling with Cdc42 and
requires only a single injection [34]. We found that CASIN administration led to a ~6-fold
increase of phenotypically defined LT-HSCs (LSKCD150+CD48−CD41−) in PB 2 h after IV
injection, whereas AMD3100 caused a ~5-fold increase of mobilization of phenotypic HSCs
(Fig. 6b). More importantly, we sought to determine the functionality of the HSCs mobilized
by CASIN or AMD3100. To this end, PB harvested from the vehicle, CASIN or AMD3100treated mice were analyzed in a transplant assay to determine radioprotection by
transplanted HSCs in lethally irradiated recipient mice. Both the CASIN and AMD3100
mobilized HSPCs were found capable of rescuing lethally irradiated mice, while transplant
of PB from vehicle-treated mice resulted in death of the recipients in 4 weeks (data not
shown). The primary recipients of transplanted PB from CASIN or AMD3100 mobilized
mice showed comparable, over 80% donor-derived blood cells in PB and BM in multiple
lineages (Fig. 6c and Figures S8A, S8B). Remarkably, the CASIN-mobilized HSCs
reconstituted over 90% of the LSKCD34− compartment in the primary recipients (Fig. 6d),
indicating a long-term reconstitution potential of CASIN-mobilized HSCs. In addition,
expression of CD26 in LSK population of BM cells or serum SDF-1α level did not change
after CASIN injection (Figures S8C, S8D), suggesting that CASIN does not affect CD26mediated effects like G-CSF or serum SDF-1α content [35, 36]. Although CASIN displayed
only a slight improvement in mobilization capacity for phenotypic HSCs over AMD3100
(sixfold vs fivefold; Fig. 6b), secondary transplant of the BM cells from primary recipients
showed that CASIN-mobilized HSCs were superior in quality to those mobilized by
AMD3100, as they were able to maintain over 90% PB or BM chimerism of various
lineages in the secondary recipients 6 months post transplant, whereas AMD3100-mobilized
PB resulted in only ~15% and 35% chimerism in the BM and PB, respectively (Fig. 6e, f).
When CASIN was applied to mice in combination with AMD3100 or G-CSF, an additive
effect in mobilizing HSPCs to PB was detected by CFU assays (Fig. 6g, h). Taken together,
these data show that pharmacological inhibition of Cdc42 by CASIN leads to a transient
mobilization of LT-HSCs with a superior quality.

Discussion

Author Manuscript

HSC mobilization is a standard procedure in BM transplantation for the treatment of many
hematologic diseases, including BM failure syndromes and leukemia [9–11]. Current
clinical HSC mobilization utilizes only G-CSF and less frequently AMD3100 as
mobilization agents with limitations in efficacy and patient application [9, 17, 19, 21]. There
is a great need for improved HSC mobilization regimens. We report here that the chemical
inhibitor CASIN specifically and reversibly inhibits Cdc42 activity, which can transiently
mobilize long-term engraftable HSCs. There are several findings that highlight the
significance of our study: (1) CASIN binds specifically to Cdc42 and competitively
interferes with its guanine nucleotide exchange activity; (2) CASIN reversibly inhibits
Cdc42 activity by suppressing actin polymerization, adhesion, and directional migration; (3)
CASIN transiently mimics Cdc42 knockout phenotype in inducing HSPC egress from
mouse BM; (4) CASIN administration to mice mobilizes HSCs with better long-term
reconstitution potential than those mobilized by AMD3100.
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Core values of a chemical inhibitor or probe include its specificity and reversibility, which
are the causal factors for side effects or toxicity. We demonstrated that CASIN can
specifically and transiently inhibit Cdc42 activity without notable effects on the closely
related Rac1 or RhoA. To date, several Cdc42 inhibitors have been reported. The first
identified small molecule ML141 (CID-2950007) has been shown to inhibit nucleotide
binding of Cdc42 GTPase; however, ML141 also exhibits low-micromolar potency and
selectivity against other members of the Rho family of GTPases, including Rac1, Rab2, and
Rab7 [37, 38]. In addition, recent studies show that ML141 fails to substantially reduce
Cdc42 activity and alleviate cell migration [39]. The second Cdc42 inhibitor AZA1
suppresses both Cdc42 and Rac1 activities in a dose-dependent manner [40]. Another small
molecule, ZCL278 specifically targets Cdc42-intersectin interaction and inhibits Cdc42mediated cellular processes, but its action is not reversible [41]. Finally an inhibitor targeting
the activated Cdc42-associated kinase 2 (ACK-2) not only binds Cdc42 in the GTP-bound
form but also interacts with clathrin and influences clathrin assembly [42, 43]. In the present
study, we show that CASIN specifically binds to purified Cdc42 protein but does not bind to
other Rho GTPases, including RhoA, Rac1, RhoJ, RhoU or RhoV, nor the Cdc42 guanine
nucleotide exchange factor (GEF) intersectin (Fig. 1b, c and S2). Furthermore, CASIN
inhibits Bradykinin-induced filopodia formation mediated by Cdc42 in WT cells but shows
no effect on Cdc42−/− cells (Figure S3). More importantly, CASIN does not show any
detectable effects on Cdc42−/− HSPCs in multiple functional assays, and CASIN
administration to mice mimics Cdc42 knockout to transiently mobilize HSCs and shows no
detectable toxicity (Figure S6, S7) nor effects on multi-lineage blood differentiation (Fig
S8). Since CASIN has a rather shorter lifetime by the i.v. injection protocol (Figures S5) and
since Cdc42 activity is transiently and reversibly suppressed by CASIN, CASIN can be
repeatedly administered to transplant recipients without causing insensitivity. Therefore, the
stringent criteria in specificity and reversibility demonstrated by CASIN distinguishes it
from other Cdc42 chemical inhibitors.

Author Manuscript

Another intriguing finding of our study is that CASIN appears superior to AMD3100 in
producing functional long-term HSCs in the mouse transplantation model. Previous studies
have demonstrated that while Cdc42 inhibitor ML141, which inhibits nucleotide binding of
Cdc42 alone only triggers modest HSPC mobilization, combination of G-CSF and ML141
significantly increases HSPC counts and colony-forming units in PB, as compared to mice
treated with G-CSF alone [44]. This might be, at least in part, due to non-specific nature of
ML141. Our present results demonstrate that CASIN specifically inhibits Cdc42 activity
through inhibiting Cdc42 guanine nucleotide exchange activity. Although, the PB containing
mobilized HSCs from both CASIN- and AMD3100-treated donor mice were capable of
rescuing the lethally irradiated primary recipient mice, the CASIN-mobilized PB was able to
maintain over 90% PB or BM chimerism of various lineages, including the stem cellenriched LSK compartment, in the secondary recipients 6 months post transplant. In
comparison, the AMD3100-mobilized PB resulted in only ~15% and 35% chimerism in the
BM and PB, respectively, and almost undetectable donor LSK cell population in the BM of
the secondary recipients (Fig. 6). It should be noted that our study compared the effects of
CASIN to those with a single dose of AMD3100. In this context, further detailed
optimization of CASIN mobilization protocol compared with the AMD3100 multi-dosage
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protocol may reveal additional differences and similarities. Our results with CASIN in
mobilizing functional HSCs anchors a recent study reporting that a CXCR2 agonist, GROβ
in combination with AMD3100 are more effective than G-CSF in mobilizing engraftable
HSCs in mice [22]. However, GROβ + AMD3100 shows disadvantage in mobilizing total
hematopoietic progenitor (LSK) cells and phenotypic (SLAM LSK) HSCs compared to GCSF [22]. Thus, it seems that CASIN, acting as a single agent, can be as potent as the
combination regimen of GROβ + AMD3100 in mobilizing functional hematopoietic stem
and progenitor cells from the BM to the peripheral.

Author Manuscript

Our present study demonstrates that CASIN is safe and effective in mobilizing blood
progenitors in vivo without detectable toxicity or affecting multi-lineage blood cell
differentiation (Fig S6). In addition to its application in mouse model, we recently show that
CASIN effectively and transiently mobilizes xenografted human CD34+ hematopoietic
progenitor cells to the PB 1 h after injection [45]. Furthermore, conditioning with CASIN
significantly facilitates engraftment of human blood progenitors in a transplant model
without any myeloablation [45]. Although further improvement on its potency and better
understanding the benefits of its short half-life (reversibility) in vivo are needed, we believe
that CASIN may represent a safe and improved pre-conditioning agent for future human
hematopoietic stem cell transplantation.
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A major challenge for successful BM transplantation is effective mobilization and harvesting
of donor HSCs with sufficient number and functional quality. Novel methods of HSC
mobilization and improved engraftment are needed for treatment of blood diseases through
BM transplantation, especially for BM failure and leukemia patients who have limited stem
cell numbers and are intolerable to intensive pre-conditioning regimens. In this report, we
provide evidence that CASIN specifically and transiently inhibits Cdc42 activity and acts as
a single agent to effectively mobilizing phenotypic and functional HSCs to the peripheral.
Since our previous genetic studies have established that Cdc42 is essential for the retention
of HSCs in the BM niche [25, 26], CASIN may prove to be a new method for blood stem
cell collect and transplantation that may significantly impact on future BM transplantation.
Specifically, CASIN would improve both sides of the transplant practice—providing a new
way to mobilize HSCs from donors and improving engraftment efficiency in recipients
without increasing treatment-related toxicity.
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Fig. 1.
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Chemical and genetic evidence that CASIN specifically and reversibly inhibits Cdc42
activity. a Chemical structure of CASIN. b Microscale thermophoresis measurement of
CASIN binding to purified Cdc42 protein. Fluorescently labeled Cdc42, Rac1, or RhoA
(200 nM) was subjected to titration of increasing concentrations of CASIN. The relative
changes in thermophoresis were traced. Results are representative of at least three
independent experiments. c Guanine nucleotide exchange reaction was performed using
fluorescent BODIPY FL-GDP bound to Cdc42 (50 nM), catalyzed by intersectin (INTN; 9
nM) (left) or using fluorescent BODIPY FL-GDP bound to RhoA (50 nM), catalyzed by
LARG (10 nM) (right) in the presence or absence of CASIN (5 or 25 μM). Results are
representative of at least three independent experiments
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Fig. 2.

CASIN inhibits Cdc42 activity, F-actin polymerization and cell polarity of hematopoietic
cells. a Isolated low-density bone marrow (LDBM) cells from WT C57Bl/6 mice were
cultured overnight in a medium without cytokines. The effect of CASIN on Cdc42 activity
as determined by GST-Pak1 effector-domain pull-down assays in the LDBM cells stimulated
with or without SDF-1α (100 ng/ml, 15 min), SCF (20 ng/ml, 15 min), or fibronectin (100
nM, 15 min) in the presence of CASIN (5 μM). The quantification of the relative levels of
Cdc42-GTP or Rac1-GTP to Cdc42 or Rac1, respectively, was performed by densitometry
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using the NIH J Image software. b Quantification of Cdc42 activity determined by Cdc42
effector-domain pull-down assays in LDBM cells with or without SDF-1α stimulation (100
ng/ml, 15 min) and/or CASIN treatment (5–10 μM). After CASIN treatment, some samples
were washed once with PBS, and then challenged with SDF-1α. r: recovery after the wash.
Error bars represent standard deviations. Results are means ± SD from three independent
experiments. c Effect of CASIN on the polarity of blood progenitors. CASIN at indicated
increasing concentrations was added to cultured Lin−Kit+ progenitors of WT C57Bl/6 mice,
and the polarized distributions of endogenous Cdc42 and Tubulin were quantified after
immunofluorescent staining for Cdc42 and Tubulin, respectively. Results are representative
of at least three independent experiments. d Effects of CASIN on F-actin polymerization in
long-term (LT)-HSCs. Freshly isolated Lin−Sca1+Kit+CD34−Flk2−LT-HSCs from WT
C57Bl/6 mice were incubated for 16 h in medium without growth factors in the present or
absence of the indicated concentrations of CASIN. The cells were then stimulated with
SDF-1α (100 ng/ml) for 15 min before fixation. Immunofluorescence staining of F-actin by
Fluorescein-phalloidin and Nuclei with DAPI were carried out. Cells with polymerized
cortical F-actin distribution were quantified. n = 20–25 cells in each group. Results are
representative of at least three independent experiments. e CASIN does not alter the BFU-E,
CFU-GM, or CFU-GEMM activity of WT C57Bl/6 LDBM cells. LDMCs were treated with
different doses of CASIN for 2 h followed by CFU assay using methycellulose medium
supplemented with rmSCF, rmIL-3, rhIL-6, and ehEPO in triplicate in 35 mm-gridded
dishes. Colonies were enumerated on day 7. Results are representative of at least three
independent experiments
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Fig. 3.
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CASIN dose-dependently suppresses adhesion and migration of blood progenitors. a
Effector domain pull-down assay for Cdc42 and Rac1 activities in Cdc42+/+ and Cdc42−/−
murine LDBM cells with or without SDF-1α stimulation (100 ng/ml, 15 min) and/or CASIN
treatment (10 μM). The relative Cdc42-GTP and Rac1-GTP levels in each sample were
normalized to that of the Cdc42+/+ cells without stimulation and CASIN treatment. Results
are representative of at least three independent experiments. b, c Effects of CASIN on
adhesion (to fibronectin fragment CH296) (b) and migration (toward an SDF-1α gradient)
(c) of murine BM-derived colony-forming progenitors from Cdc42+/+ or Cdc42−/− mice (n =
3). Results are representative of at least three independent experiments. d CASIN does not
affect differentiation and proliferation of progenitor activities of LDBM cells. Comparison
of the effects of CASIN on CFU-C (mix) activities between Cdc42+/+ and Cdc42−/− LDBM
cells. CASIN at 0, 5, 10 μM concentrations were examined in each condition. Results are
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representative of at least three independent experiments. e Immunoblots of Cdc42 effectors
p-PAK1, p-WASP, and p-aPKC in CASIN-treated (5 or 10 μM) WT Lin− cells, compared
with Cdc42−/− Lin− cells, after SDF-1α stimulation (100 ng/ml, 15 min). All error bars
represent standard deviations. Results are representative of at least three independent
experiments
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Fig. 4.
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CASIN specifically inhibits Cdc42 activity and Cdc42-mediated signaling in HSPCs. a
SDF-1α-induced F-actin polymerization analyzed by FACS analysis (n = 3) in WT murine
Lin− cells with or without CASIN treatment (0, 5, 10 μM), in comparison to that of Q61Ltransduced or Cdc42−/− cells. S SDF-1α stimulation at 100 ng/ml for 15 min. Results are
representative of at least three independent experiments. b CASIN binding to Cdc42 was
simulated by a structural modeling with the critical Met45 residue involved in CASIN
binding, which interfaces with DOCK GEF binding surface as indicated. c Relative binding
of CASIN to Cdc42 point mutants in comparison to wild-type Cdc42. Relative binding
affinity was normalized to that of wild-type Cdc42. Results are representative of at least
three independent experiments. d Representative immunoblots of effector domain pull-down
assays for Cdc42 activity in 293T cells transfected with M45E Cdc42, with or without serum
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stimulation (20% FBS, 15 min) and/or CASIN treatment (5 μM). The endogenous WT
Cdc42-GTP level was measured in parallel to M45E-GTP in the same samples. Results are
representative of at least three independent experiments
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CASIN phenocopies Cdc42 gene deletion to induce mobilization of long-term HSCs. a
Pharmacokinetics of CASIN in mouse sera determined by HPLC-ESI-MS/MS after CASIN
administration (1.2 mg/Kg) by IV. Results are representative of at least three independent
experiments. b Representative immunoblots of effector-domain pull-down assays for Cdc42
and Rac1 activities in LDBM cells of CASIN-or vehicle-treated mice. LDBMCs were
isolated from the mice 2 h after CASIN administration (1.2 mg/ Kg, IV) followed by Cdc42
effector pull-down assay with or without PBS wash. Results are representative of at least
three independent experiments. c Mobilization of hematopoietic progenitor CFU activities in
peripheral blood post-CASIN injection (1.2 mg/kg) (n = 6, 3, 4, 7, and 4); **P < 0.01, basal
vs 2 h. d CFU progenitor activities of splenocytes 2 h after CASIN treatment (1.2 mg/kg,
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IV) (n = 3). Results are representative of at least three independent experiments. e CASIN
induces mobilization of colony-forming progenitors in WT mice but does not show additive
effects in Cdc42−/− mice. Peripheral blood from WT and Cdc42−/− mice (5 days after
polyI:C injections) that were subjected to either vehicle or CASIN treatment, were collected
2 h after the vehicle or CASIN IV administration. The colony-forming activities of the PB
cells were assayed. CASIN did not cause a detectable effect in the Cdc42−/− mice under
conditions where WT mice were responsive. Results are representative of at least three
independent experiments. f CASIN mobilizes different lineages of cells. Effects of CASIN
on blood cell mobilization were determined by flow cytometry and complete blood count 2 h
after CASIN administration (1.2 mg/Kg, IV) in comparison to controls (n > 6). Left:
Numbers of WBCs, RBCs, and PLTs determined by blood counter (HEMAVET) 2 h after
CASIN administration (IV, 0.5 mM, 200 μl/20 g mouse weight) in comparison to controls.
Middle and right: Numbers of myeloid-, erythroid-, T-, and B- lineage cells determined by
flow cytometry (CD11b, Ter119, CD3, and B220) 2 h after CASIN administration (1.2
mg/kg, IV) in comparison to controls in both BM and PB. Results are representative of at
least three independent experiments
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Fig. 6.

CASIN-mobilized HSCs are superior in functionality to those mobilized by AMD3100. a
Mobilization of hematopoietic progenitor CFU activities in peripheral blood post-CASIN,
AMD3100 or G-CSF injection. PB from the mice treated with CASIN (1.2 mg/kg, IV),
AMD3100 (5 mg/kg, IP), or G-CSF injection (100 μg/kg per day once a day for 5 days, IP)
were subjected to CFU assay. (n = 5 per group). Results are representative of at least three
independent experiments. b Quantification of LSKCD150+CD48−CD41− cells in PB of mice
mobilized with CASIN, AMD3100, or vehicle 2 h post injection of CASIN (1.2 mg/kg, IV)
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(n = 8), AMD3100 (5 mg/kg, IP) (n = 8), or vehicle (control, n = 7). c The percentages of
CD45.2 donor leukocytes in CD45.1-recipient mice in both PB and BM of lethally irradiated
primary recipients transplanted with PBMCs (500 μl blood) from mice subjected to CASIN
or AMD3100 injection. Results are representative of at least three independent experiments.
d The percentages of CD45.2 donor LSKCD34− HSCs in CD45.1-recipient mice in the BM
of lethally irradiated primary recipients transplanted with PBMCs (500 μl blood) from mice
subjected to CASIN or AMD3100 injection. Results are representative of at least three
independent experiments. e CASIN and AMD3100 mobilized long-term HSC activities were
assayed by secondary transplantation into lethally irradiated BoyJ mice (5 × 106 donor BM
cells from primary recipients for each secondary recipient; n = 7 and 6 for CASIN and
AMD3100 groups, respectively). The percentages of CD45.2+ donor cells in both PB and
BM of secondary CD45.1-recipients were analyzed by FACS 6 months after the secondary
transplant. Results are representative of at least three independent experiments. f The Gr1+,
Ter119+, and B220+ lineages of CD45.2 donor cells in PB of secondary CD45.1-recipients
were analyzed 6 months after the secondary transplant. Results are representative of at least
three independent experiments. g Mobilization of progenitor CFU activity by AMD3100
alone or in combination with CASIN. AMD3100 (5 mg/kg, IP) (n = 6) or AMD3100 (5
mg/kg, IP) in conjunction with CASIN (1.2 mg/kg, IV) (n = 6) treated mice were analyzed
for CFU-C activities in PB 2 h after the respective treatment. Results are representative of at
least three independent experiments. h Mobilization of progenitor CFU activity by G-CSF
alone or in combination with CASIN. G-CSF (100 μg/kg per day once a day for 5 days, IP)
(n = 4) or G-CSF in conjunction with CASIN (1.2 mg/kg, once in day 6 of G-CSF, IV) (n =
5) treated mice were analyzed for CFU-C activities in PB 2 h after the CASIN treatment.
Results are representative of at least three independent experiments
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